Allison Wheeler, MD
Pediatric Hematology-Oncology · Seattle, WANPI 1174736912
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $206,017 of the $317,753 with a category attached, or 64.8%. 18 manufacturers reported payments, led by Novo Nordisk Health Care AG at 35.3% of the total. 2025 is the largest year on record at $115,432, more than ten times the $8,167 reported in 2019. Among pediatric hematology-oncology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 212 payments — averaging $1498.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk Health Care AG$112K
- Novo Nordisk$30K
- Sanofi$28K
- Octapharma USA, Inc.$24K
- Bayer$21K
- Genentech USA, Inc.$21K
- plus $82K from 12 others
Across 1,108 payments — averaging $899.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$647K
- Cerus Corporation$174K
- Biomarin Pharmaceutical Inc.$69K
- Sanofi US Services Inc.$48K
- HEMA Biologics, LLC$24K
- Regeneron$14K
- plus $19K from 2 others
What the payments were for
- Consulting fees$206,01765%
- Speaking & faculty fees$25,4298%
- Travel & lodging$79,42625%
- Food & beverage$5,4742%
- Education$210%
- Gifts$1,3870%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk Health Care AG | 42 | $112,323 |
| Novo Nordisk | 22 | $29,878 |
| Sanofi | 21 | $28,191 |
| Octapharma USA, Inc. | 9 | $23,843 |
| Bayer | 27 | $20,711 |
| Genentech USA, Inc. | 21 | $20,639 |
| Sanofi US Services Inc. | 1 | $19,805 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $16,375 |
| Pfizer | 17 | $16,070 |
| CSL Behring | 7 | $10,467 |
| Novo Nordisk AS | 7 | $5,954 |
| Cerus Corporation | 3 | $5,555 |
| Bioverativ Therapeutics Inc. | 1 | $2,958 |
| HEMA Biologics, LLC | 8 | $2,539 |
| Shire North American Group Inc | 11 | $1,399 |
| Spark Therapeutics, Inc. | 2 | $855 |
| Bio Products Laboratory USA, Inc. | 1 | $172 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NovoSeven$24,891
- HEMLIBRA$19,964
- ALTUVIIIO$19,805
- QFITLIA$14,423
- FIBRYGA$12,757
- HYMPAVZI$10,446
- WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN)$10,187
- Jivi$9,762
- HEMGENIX$7,455
- Alhemo$6,346
- INTERCEPT BLOOD SYSTEM FOR PLATELETS$5,555
- ADVATE$5,100
- NovoSeven RT$2,720
- SevenFact$2,500
- ADYNOVATE$1,600
- BENEFIX$1,110
- REBINYN$1,020
- NUWIQ$847
- VYNDAQEL$750
- Coagadex$172
How this compares
$317,753 in reported general payments places this provider in the 95th percentile of 60 pediatric hematology-oncology providers in Washington.
See all pediatric hematology-oncology providers in Washington →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 11 | $1,564 |
Paid to pharmacies, not to this prescriber.
Other pediatric hematology-oncology in Seattle
- Rachel RauSeattle$87K
- Paul CarpenterSeattle$40K
- Kasey LegerSeattle$19K
- Douglas HawkinsSeattle$13K
- Rebecca GardnerSeattle$11K
- Michael BenderSeattle$9K
- Navin PintoSeattle$8K
- Whitney EngSeattle$8K
- Kristin MaherSeattle$7K
- Kavita DhodapkarSeattle$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.